Differential expression of the chemokines GRO-2, GRO-3, and interleukin-8 in colon cancer and their impact on metastatic disease and survival

Abstract

In accordance with earlier findings, we report here a significantly increased expression of GRO-2, GRO-3, and IL-8 in colon carcinoma as compared to normal tissue. Furthermore, GRO-3 was related to metastasis formation, and IL-8 was associated with survival, suggesting a potential predictive power of these markers.

Stemness-Related Transcriptional Factors and Homing Gene Expression Profiles in Hepatic Differentiation and Cancer

“…CXCL2 relative expression has been found to be low in breast cancer (19) and elevated in an estrogen receptor-positive breast cancer type in another study (20). The same levels of expression have been found in normal and adenocarcinoma samples of the colon (21), while it was significantly elevated in colon cancer compared with normal adjacent tissue, facilitating cancer cell invasion and metastasis, and correlated with an unfavorable outcome in other studies (22,23). However, little is known about the expression of CXCL2 in HCC and its correlation with the clinical disease outcome.…”

Custom Design of a GeXP Multiplexed Assay Used to Assess Expression Profiles of Inflammatory Gene Targets in Normal Colon, Polyp, and Tumor Tissue

“…[13][14][15][16][17] They also have been reported to be involved in angiogenesis 27 and metastasis. 28,29 Notably, Table 1. GeXP hInflamPlex data normalized to GAPDH (A), real-time PCR data normalized to GAPDH (B), GeXP hInflamPlex data normalized to B2M (C), and real-time PCR data normalized to B2M (D).…”

G31P, an Antagonist against CXC Chemokine Receptors 1 and 2, Inhibits Growth of Human Prostate Cancer Cells in Nude Mice

“…CXCL8 and the two CXCL8 receptors are expressed in prostate cancer tissues (Murphy et al 2005). Furthermore, among the ELR-CXC chemokines, CXCL1-3 [growth-related oncogene (GRO)-α, -β, and -γ] are highly expressed in colon cancer cells (Doll et al 2010) and also in tumor-infiltrating neutrophils, tumor-associated macrophages, and endothelial cells, suggesting that multiple ELR-CXC chemokines can regulate the tumor microenvironment (Brat et al 2005;Charalambous et al 2005). Clinical studies have confirmed the increased expression of CXCL8 in the more advanced stages of cancers, which indicates that suppression of ELR-CXC chemokine activity may be an important therapeutic approach for aggressive and metastatic tumors .…”